The initial success of the copyright undeniably transformed the drug landscape, but betting in companies heavily reliant on unbranded versions presents a uncertain picture. While early earnings were impressive, the expiration of patents and the appearance of discounted alternatives have weakened market share. Consequently, a thorough assessment of